Brian C Stephenson sold $93k of BBIO
Secretary, Treasurer & CFO at BridgeBio Pharma, Inc.. 4,156 shares at an average of $22.41, traded Nov 19, 2024, filed Nov 20, 2024.
Score components
- +22RoleCFO
- +10Trade size$93k at market
- 0Share of holdings soldSold 4.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +15.0%, 3m +57.5%, 6m +42.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-129452, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | SOpen-market sale Common Stock10b5-1 | -4,156 | $22.41 | $93k | 93,758 | Nov 20, 2024 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 6Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $143k 2,000 shares | -1% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.5M 80,000 shares | -12% | |
| 35Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $624k 8,671 shares | -54% | |
| 40Moderate | BridgeBio Pharma, Inc. | Andrea Ellis director | $4.2M 64,921 shares | -78% | |
| 40Moderate | BridgeBio Pharma, Inc. | Hannah Valantine director | $1.7M 25,484 shares | -77% | |
| 21Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $132k 2,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $2.0M 28,053 shares | -11% | |
| 16Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $38k 510 shares | -0% | |
| 27Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $755k 10,000 shares | -46% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.